65,437 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.51; -0.36 Percent A1C — p=0.006
Familial Hypercholesterolemia - Homozygous
Primary: Percent Change in LDL-C — -42.2 Percent change
Type 2 Diabetes Mellitus · Inadequate Glycaemic Control
Primary: Change From Baseline in HbA1c at Week 24 — -1.03; -0.63; -0.69 Percentage (%) — p=<0.0001
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib — 7700; 23600 nanogram * hour per milliliter (ng*h/mL)
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 10 percent change
Advanced Solid Tumors
Primary: Steady-state Serum Concentration of Dalotuzumab at 336 Hours (C336) After the First Maintenance Dose — 4.78; 7.48; 54.57; 33.00 μg/mL
B-cell Adult Acute Lymphoblastic Leukemia (ALL) · Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) · Recurrent Adult Acute Lymphoblastic Leukemia (ALL)
Primary: Response Rate (RR) — 11 Participants
Influenza
Primary: Number of Subjects With at Least One Influenza-like-infection (ILI) Episode — 133; 243; 376; 125 Participants
Partial Onset Seizures
Primary: Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase — 1.69; 1.15; 1.58 seizures per 24 hours — p=0.4606
Infectious Diarrhoea
Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours
Hemodialysis · Hyperphosphatemia
Primary: Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment — 5.00; 5.34 mg/dL — p=0.020
Relapsing Remitting Multiple Sclerosis
Primary: Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression — 0.331; 0.505 confirmed relapses…
HIV
Primary: Change in Patient Activation Measure (PAM) — 73.35; 70.53 score on a scale
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol — 71.7; 70.6 picogram per milliliter (pg/ml)
Hemodialysis Patients With Hyperphosphatemia
Primary: Incidence of Adverse Events — 152 Participants